AxoGen (AXGN) to Release Quarterly Earnings on Thursday

AxoGen (NASDAQ:AXGN) is expected to issue its Q1 2025 quarterly earnings data before the market opens on Thursday, May 1st. Analysts expect the company to announce earnings of ($0.01) per share and revenue of $48.35 million for the quarter.

AxoGen Stock Down 1.3 %

AXGN stock opened at $16.18 on Tuesday. The company has a market cap of $717.49 million, a PE ratio of -50.56 and a beta of 1.00. The company has a quick ratio of 2.47, a current ratio of 3.74 and a debt-to-equity ratio of 0.67. AxoGen has a twelve month low of $5.55 and a twelve month high of $21.00. The business’s 50-day simple moving average is $17.38 and its 200 day simple moving average is $16.21.

Insiders Place Their Bets

In other news, Director Amy Mcbride Wendell sold 5,000 shares of the company’s stock in a transaction on Monday, March 3rd. The stock was sold at an average price of $20.02, for a total transaction of $100,100.00. Following the transaction, the director now owns 97,899 shares of the company’s stock, valued at $1,959,937.98. This represents a 4.86 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, insider Erick Wayne Devinney sold 15,111 shares of the company’s stock in a transaction on Wednesday, March 19th. The shares were sold at an average price of $17.50, for a total value of $264,442.50. Following the transaction, the insider now directly owns 217,762 shares in the company, valued at $3,810,835. This trade represents a 6.49 % decrease in their position. The disclosure for this sale can be found here. Insiders own 7.00% of the company’s stock.

Analyst Ratings Changes

A number of equities analysts have recently issued reports on AXGN shares. Canaccord Genuity Group increased their target price on AxoGen from $22.00 to $26.00 and gave the stock a “buy” rating in a report on Wednesday, February 26th. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $24.00 price target on shares of AxoGen in a research note on Wednesday, March 5th. Finally, Lake Street Capital initiated coverage on AxoGen in a research note on Monday, March 17th. They issued a “buy” rating and a $30.00 price target on the stock. Six investment analysts have rated the stock with a buy rating, According to MarketBeat, the stock currently has a consensus rating of “Buy” and an average target price of $22.60.

AxoGen Company Profile

AxoGen, Inc, together with its subsidiaries, develops and commercializes technologies for peripheral nerve regeneration and repair worldwide. The company’s products include Avance Nerve Graft, a biologically active off-the-shelf processed human nerve allograft for bridging severed peripheral nerves without the comorbidities associated with a second surgical site; AxoGuard Nerve Connector, a porcine submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed peripheral nerves; AxoGuard Nerve Protector, a porcine submucosa ECM product that is used to wrap and protect damaged peripheral nerves, as well as reinforces the nerve reconstruction while preventing soft tissue attachments; and Axoguard HA+ Nerve Protector, a processed porcine submucosa ECM base layer with a hyaluronate-alginate gel coating designed to provide short- and long-term protection for peripheral nerve injuries.